All In Biotech

Drug Trial Radar · NCT07001995

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

A Single-center, Single-arm Phase II Study of Limertinib Plus Carboplatin and Etoposide in EGFR-mutant NSCLC Patients With SCLC Transformation After EGFR-TKI Progression

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.

Conditions

  • Small Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer NSCLC

Interventions

  • limertinibDrug

    limertinib 80 mg

  • etoposide and carboplatinDrug

    etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.